Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2925| Título : | Treatment of pulmonary arterial hypertension using extemporaneous formulation of sildenafil in Mexican children |
| Creador: | Juárez Olguín, Mateo Hugo |
| Nivel de acceso: | Open access |
| Palabras clave : | Administración Oral Adolescente Niño Preescolar Relación Dosis-Respuesta a Droga Composición de Medicamentos - métodos Femenino Estudios de Seguimiento Humanos Hipertensión Pulmonar - sangre Hipertensión Pulmonar - tratamiento farmacológico Hipertensión Pulmonar - fisiopatología Masculino Citrato de Sildenafil - administración & dosificación Citrato de Sildenafil - efectos adversos Citrato de Sildenafil - sangre Citrato de Sildenafil - uso terapéutico Factores de Tiempo Resultado del Tratamiento Vasodilatadores - administración & dosificación Vasodilatadores - uso terapéutico Administration, Oral Adolescent Child Child, Preschool Dose-Response Relationship, Drug Drug Compounding- methods Female Follow-Up Studies Humans Hypertension, Pulmonary - blood Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - physiopathology Male Sildenafil Citrate - administration & dosage Sildenafil Citrate - adverse effects Sildenafil Citrate - blood Sildenafil Citrate - therapeutic use Time Factors Treatment Outcome Vasodilator Agents - administration & dosage Vasodilator Agents - therapeutic use Niños Hipertensión arterial pulmonar Sildenafil Unitaria dosis Children Pulmonary arterial hypertension Sildenafil Unitary doses |
| Descripción : | Pulmonary arterial hypertension (PAH) is a sickness with high rate of mortality that consists of elevation in pressure of the vessels through which blood flows to the lung. Sildenafil is a therapeutic option for the treatment of PAH in children for the fact that it relaxes the blood vessels and thereby improves pulmonary blood flow. The aim was to analyze the clinical behavior of an extemporaneous formulation of sildenafil as a therapeutic option in children with PAH, twelve children with PAH were studied. The ages and weights of the children ranged from 5 to 15 years and from 13 to 27 kg. All patients received a capsule of 1 mg/kg of sildenafil prepared as extemporaneous formulation in the pharmacology laboratory. Blood levels of sildenafil were analyzed in order to evaluate its availability of developed formulation. Management has derived from physiopathological knowledge and clinical presentations of patients. The mean maximum concentration was 550 ng/ml which is greater than levels reported in adults. Moreover, a therapeutic monitoring of sildenafil was carried out in order to establish an adequate therapeutic range for children and to show that dosages prepared extemporaneously meet the therapeutic needs for the management of PAH. With an average follow-up of once every 2 months, it was found that the evolution of the patients was favorable and without adverse effects that could put their life at risk. The management of PAH with sildenafil prepared as extemporaneous formulation might be considered as a good therapeutic option. © 2015, Springer Science+Business Media New York. |
| Colaborador(es) u otros Autores: | Camacho Reyes Laura Roldan Arce Arturo Calderon Guzman David |
| Fecha de publicación : | 2015 |
| Tipo de publicación: | Artículo |
| Formato: | |
| Identificador del Recurso : | 10.1007/s00246-015-1113-9 |
| Fuente: | Pediatric Cardiology 36(5):1019 - 1023 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2925 |
| Idioma: | eng |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.